A deal for Grail could be Illumina’s next shot at diversifying 

Nine months after abandoning its bid to acquire PacBio, tools company Illumina is in talks to bring its spinout Grail back into the fold, according to a report.

Doing so wouldn’t come cheap. The offer would likely come at a premium to the $6 billion valuation Grail Inc. garnered from its series D round in May, according to a Bloomberg article that cited undisclosed sources...